Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

Genitourinary Cancer

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data

Ann Oncol

Jones C, Dutey-Magni P, Murphy LR, Murray ML, Brown JE, McCloskey E, Brown M, Amos CL, Gilbert DC, Jones RJ, Cross W, Matheson D, Millman R, Parmar MKB, Attard G, Sydes MR, Brown LC, James ND, Clarke NW, Sachdeva A, STAMPEDE Trial Investigators

doi: 10.1016/j.annonc.2025.07.005

Leukemia

Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

Leukemia

Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha V, Papayannidis C, Leonard JT, Baer MR, Ribera JM, McCloskey J, Wang J, Gao S, Rane D, Guo S

doi: 10.1038/s41375-025-02608-4

Genitourinary Cancer

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

J Clin Oncol

Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL

doi: 10.1200/JCO.24.00365

Leukemia

Risk factors and clinical implications of hyperglycemia during induction therapy in pediatric acute lymphoblastic leukemia

Int J Cancer

Taher YY, Lehmann L, Zamzam M, Mona Atteya H, Reda H, Abuelhassan AA, Sidhom I, El-Haddad A

doi: 10.1002/ijc.70084

Leukemia

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation

Am J Hematol

Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM

doi: 10.1002/ajh.27561

Leukemia

Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort

J Natl Cancer Inst

Zheng DJ, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huang YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Wang X, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD

doi: 10.1093/jnci/djaf234

Leukemia

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Blood

Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell NH, Dillon RJ, Thomas I, Ossenkoppele GJ, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Villaverde Ramiro Á, Tur Giménez L, Gurnari C, Bullinger L, Hernandez JM

doi: 10.1182/blood.2024026186

Genitourinary Cancer

High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial

Virchows Arch

Hommerding O, Bernhardt M, Kreft T, Scherping A, Abbas M, Baretton G, Bräsen JH, Breyer J, Darr C, Dressler FF, Ellinger J, Erber R, Esposito I, Hartmann A, Hartmann W, Heitplatz B, Kreipe H, Lafos M, Linxweiler J, Lopez-Cotarelo C, Sailer V, Reis H, Saar M, Schildhaus HU, Schlack K, Schmid M, Seidl M, Semjonow A, Sommer U, Stahl PR, Tischler V, Weber F, Wulf AL, Wullich B, Kristiansen G

doi: 10.1007/s00428-024-03999-y

Breast Cancer

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial

Ann Oncol

Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D

doi: 10.1016/j.annonc.2024.10.015

Related content

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data

Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Risk factors and clinical implications of hyperglycemia during induction therapy in pediatric acute lymphoblastic leukemia

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation

Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial